Drug intelligence / Profile preview

ruguotang

Development stage: Unknown
Lead developer: Hanmi Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Ruguotang is a laxative product developed and marketed by Hanmi Pharmaceutical. It is one of the company's major products, alongside others such as Mamiai (a digestive supplement for children) and Etanjing (a cough medicine). The specific active ingredients, mechanism of action, and detailed pharmacological profile are not provided in the available sources. However, as a laxative, its primary indication is to relieve constipation or promote bowel movements[2][3].

Brand names: Ruguotang

Beyond the preview

Go deeper on ruguotang.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ruguotang.

Explore the full profile